9F0912A, 0914BResponsible DepartmentDepartment of DDS Pharmaceutical DevelopmentResearch PartnersShionogi Pharma Co., Ltd.2424The aim of our department is the development of current good manufacturing practice (cGMP) manufacturing processes for novel lipid-based nano-formulations, including liposomes and lipid nano-particles (LNPs), targeting immunocompetent cells for the treatment of cancer and transplant rejection. Our innovative and patented in-line manufacturing technologies, SOLID and SQUID, have proven to be promising for cGMP production of liposomal investigational new drugs. Our technologies will accelerate the “Translational drug development” in which laboratory reagents are re-developed to clinical and commercial pharmaceuticals, and therefore lead to prompt approval of new drugs.A-22MATSUZAKI TakashiSpecially Appointed Associate ProfessorDepartment of DDS Pharmaceutical DevelopmentDevelopment of cGMP manufacturing process for novel lipid-based nano-medicine by taking advantage of the in-line manufacturing platform technology
元のページ ../index.html#25